87 related articles for article (PubMed ID: 17723165)
21. The use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia.
Zhang P
J Biol Regul Homeost Agents; 1999; 13(4):195-200. PubMed ID: 10703942
[TBL] [Abstract][Full Text] [Related]
22. Apoptosis induction by (+)alpha-tocopheryl succinate in the absence or presence of all-trans retinoic acid and arsenic trioxide in NB4, NB4-R2 and primary APL cells.
Freitas RA; Silva dos Santos GA; Gimenes Teixeira HL; Scheucher PS; Lucena-Araujo AR; Lima AS; Abreu e Lima RS; Garcia AB; Jordão AA; Falcão RP; Vannucchi H; Rego EM
Leuk Res; 2009 Jul; 33(7):958-63. PubMed ID: 19013639
[TBL] [Abstract][Full Text] [Related]
23. Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia.
Zheng PZ; Wang KK; Zhang QY; Huang QH; Du YZ; Zhang QH; Xiao DK; Shen SH; Imbeaud S; Eveno E; Zhao CJ; Chen YL; Fan HY; Waxman S; Auffray C; Jin G; Chen SJ; Chen Z; Zhang J
Proc Natl Acad Sci U S A; 2005 May; 102(21):7653-8. PubMed ID: 15894607
[TBL] [Abstract][Full Text] [Related]
24. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate.
Brave M; Goodman V; Kaminskas E; Farrell A; Timmer W; Pope S; Harapanhalli R; Saber H; Morse D; Bullock J; Men A; Noory C; Ramchandani R; Kenna L; Booth B; Gobburu J; Jiang X; Sridhara R; Justice R; Pazdur R
Clin Cancer Res; 2008 Jan; 14(2):352-9. PubMed ID: 18223208
[TBL] [Abstract][Full Text] [Related]
25. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
Walz C; Sattler M
Crit Rev Oncol Hematol; 2006 Feb; 57(2):145-64. PubMed ID: 16213151
[TBL] [Abstract][Full Text] [Related]
26. Old, new drugs and new, new drugs for the new millennium.
Scheinberg DA
Curr Oncol Rep; 2000 Mar; 2(2):112-3. PubMed ID: 11122831
[No Abstract] [Full Text] [Related]
27. Delicious poison: arsenic trioxide for the treatment of leukemia.
Kwong YL; Todd D
Blood; 1997 May; 89(9):3487-8. PubMed ID: 9129058
[No Abstract] [Full Text] [Related]
28. Targeting transcription factors in acute leukemia in children.
Berman JN; Look AT
Curr Drug Targets; 2007 Jun; 8(6):727-37. PubMed ID: 17584028
[TBL] [Abstract][Full Text] [Related]
29. Acute promyelocytic leukemia: a model of molecular target based therapy.
Zhou GB; Chen SJ; Chen Z
Hematology; 2005; 10 Suppl 1():270-80. PubMed ID: 16188687
[TBL] [Abstract][Full Text] [Related]
30. Cancer agents show first-line potential.
Hampton T
JAMA; 2007 Jul; 298(4):391. PubMed ID: 17652286
[No Abstract] [Full Text] [Related]
31. Transcriptome and proteome analyses of drug interactions with natural products.
Fang H; Wang K; Zhang J
Curr Drug Metab; 2008 Dec; 9(10):1038-48. PubMed ID: 19075620
[TBL] [Abstract][Full Text] [Related]
32. Molecular pathways: induction of polyploidy as a novel differentiation therapy for leukemia.
Krause DS; Crispino JD
Clin Cancer Res; 2013 Nov; 19(22):6084-8. PubMed ID: 23963861
[TBL] [Abstract][Full Text] [Related]
33. Targeted therapies for the treatment of leukemia.
Stull DM
Semin Oncol Nurs; 2003 May; 19(2):90-7. PubMed ID: 12830733
[TBL] [Abstract][Full Text] [Related]
34. Dasatinib promotes ATRA-induced differentiation of AML cells.
Kropf PL; Wang L; Zang Y; Redner RL; Johnson DE
Leukemia; 2010 Mar; 24(3):663-5. PubMed ID: 20033056
[No Abstract] [Full Text] [Related]
35. [Treatment of leukemia with traditional Chinese drugs containing arsenic].
Zhang T; Chen G; Zhou A
Zhongguo Zhong Xi Yi Jie He Za Zhi; 1998 Oct; 18(10):581-4. PubMed ID: 11477838
[No Abstract] [Full Text] [Related]
36. Extramedullary disease and targeted therapies for hematological malignancies--is the association real?
Raanani P; Shpilberg O; Ben-Bassat I
Ann Oncol; 2007 Jan; 18(1):7-12. PubMed ID: 16790518
[TBL] [Abstract][Full Text] [Related]
37. On the assessment of dasatinib-induced autophagy in CLL.
Krause G; Hallek M
Leuk Res; 2011 Jan; 35(1):137-8. PubMed ID: 20947165
[No Abstract] [Full Text] [Related]
38. Novel agents aiming at specific molecular targets increase chemosensitivity and overcome chemoresistance in hematopoietic malignancies.
Boehrer S; Nowak D; Hoelzer D; Mitrou PS; Chow KU
Curr Pharm Des; 2006; 12(1):111-28. PubMed ID: 16454729
[TBL] [Abstract][Full Text] [Related]
39. Treatment by design in leukemia, a meeting report, Philadelphia, Pennsylvania, December 2002.
Larson RA; Daley GQ; Schiffer CA; Porcu P; Pui CH; Marie JP; Steelman LS; Bertrand FE; McCubrey JA
Leukemia; 2003 Dec; 17(12):2358-82. PubMed ID: 14562120
[TBL] [Abstract][Full Text] [Related]
40. [Development of anti-leukemic drugs and clinical studies in Japan].
Ohno R
Rinsho Ketsueki; 1999 Mar; 40(3):168-71. PubMed ID: 10222618
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
